Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2007-05-22
2007-05-22
Lambkin, Deborah C. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C514S534000
Reexamination Certificate
active
10766990
ABSTRACT:
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van Der Linder et al.
patent: 6204257 (2001-03-01), Stella et al.
patent: 6254853 (2001-07-01), Hendler et al.
patent: 6362234 (2002-03-01), Hendler
patent: 6451776 (2002-09-01), Stella et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 00/48572 (2000-08-01), None
patent: WO 00/54588 (2000-09-01), None
patent: WO 02/13810 (2002-02-01), None
Adibi, “The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function,”Gastroenterology1997, 113, 332-340.
Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices of Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech.&Prod. Mfr. 1984, 5(3) 1-9.
Anderson et al., “Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors,”J. Med. Chem. 2001, 44, 3582-3591.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm. 1979, 2, 307.
Banaszczyk et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation,”Anesth. Analg. 2002, 95, 1285-1292.
Borgeat et al., “Adjuvant Propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer,”Can. J. Anaesth. 1994, 41, 1117-1119.
Borgeat et al., “Propofol improves patient comfort during cisplatin chemotherapy. A pilot study,”Oncology1993, 50, 456-459.
Briggs et al., “An adverse Reaction to the administration of disoprofol (Diprivan),”Anaesthesia1982, 37, 1099-1101.
Brooker et al., “Propofol Maintenance to Reduce Postoperatiove Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurane/Nitrous Oxide,”Anaesth. Intensive Care1998, 26, 625-629.
Brown et al., “Role of Propofol in Refractory Status Epilepticus,”Pharmacother. 1998, 32, 1053-1059.
De la Cruz et al., “The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients,”Anesth. Analg. 1999, 89, 1050-1055.
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” 1989,Ann. Neurol. 25:351.
Gan et al., “Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea,”Anesthesiology, 1997, 87, 779-784.
Hasan et al., “Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroshock Seizures in a Rat,”Pharmacol. Toxicol. 1994, 74, 50-53.
Holtkamp et al., “Propofol in subanesthetic doses terminates Status epilepticus in a rodent model,”Ann. Neurol. 2001, 49, 260-263.
Howard et al., “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” 1989,J. Neurosurg. 71:105-112.
Krusz et al., “Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine,”Headache2000, 40, 224-230.
Kuisma et al., Propofol in prehospital Treatment of convulsive status epilepticus.Epilepsia1995, 36, 1241-1243.
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Relaease of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem. 1983, 23:61.
Langley et al., “Propofol. A review of its pharmacodynamic and Pharmacokinetic properties and use as an intravenous anaesthetic,”Drugs1988, 35, 334-372.
Leibach et al., “Peptide transporters in the Intestine and the kidney,”Ann. Rev. Nutr. 1996, 16, 99-119.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”0Science1985 228: 190-192.
Murphy et al., “The Antioxidant Potential of Propofol (2,6-Diisopropylphenol),”Br. J. Anaesth. 1992, 68, 613-618.
Peduto et al., “Biochemical and Electrophysiologic Evidence That Propofol Enchances GABAergic Transmission in the Rat Brain,”Anesthesiology1991, 75, 1000-1009.
Phelps et al., “Propofol in Chemotherapy-Associated Nausea and Vomiting,”Ann. Pharmacother. 1996, 30, 290-292.
Picard et al., “Prevention of Pain on Injection with Propofol: A Quantitative Systematic Review,” 2000, 90, 963-969.
Pop et al., “Synthesis and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-Diisopropylphenol (Propofol),”Med. Chem. Res. 1992, 2, 16-21.
Raleigh et al., “Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,”British J. Cancer, 1999, 80, Suppl. 2, 96.
Raleigh et al., “Searching for the Link Between Hypoxia and Poor Prognoses in Human Tumors,”Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, 397..
Raoof et al., “In Vivo Assessment of Intestinal Hepatic, and Pulmonary First Pass Metabolism of Propofol in the Rat,”Pharm. Res. 1996, 13, 891-895.
Sagara et al., “Propofol Hemisuccinate Protects Neuronal Cells from Oxidative Injury,”J. Neurochem. 1999, 73, 2524-2530.
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”N. Engl. J. Med., 1989, 321: 574.
Sefton, “Implantable Pumps,”CRC Crit Ref Biomed. Eng. 1987, 14:201.
Simonian et al., “Oxidative Stress in Neurodegenerative Diseases,” Pharmacol. Toxicol. 1996, 83-106.
Sutherland et al., “Propofol and Seizures,”Anaesth. Intensive Care1994, 22, 733-737.
Tomioka et al., “Propofol Is Effective in Chemotherapy-Induced Nausea and Vomiting: A Case Report with Quantitative Analysis,”Anesth. Analg. 1999, 89, 798-799.
Tramer et al., “Propofol Anaesthesia and Postoperative Nausea and Vomiting Quantitative and Systemic Review of Randomized Controlled Studies,”Br. J. Anaesth. 1997, 78, 247-255.
Trapani et al., “Propofol Analogues. Synthesis, Relationships Between Structure and Affinity for GABAAReceptors,”J. Med. Chem. 1998, 41, 1846-1854.
Trapani et al., “Water-Soluble Salts of Aminoacid Esters of the Anesthetic Agent Propofol,”Int. J. Pharm. 1998, 175, 195-204.
Verma et al., “Osmotically Controlled Oral Drug Delivery,”Drug Dev. Ind. Pharm., 2000, 26:695-708.
Walder et al., “Seizure-like phenomena and propofol,”Neurology2002, 58, 1327-1332.
Wang et al. “Propofol reduces infarct size and striatal dopamine accumulation following transient middle cerebral artery occlusion: a microdialysis study,”Eur. J. Pharmacol. 2002, 452, 303-308.
Young et al., “Propofol neuroprotection in a rat model of Ischaemia reperfusion injury,”Eur. J. Anaesthesiol. 1997, 14, 320-326.
Cundy Kenneth C.
Gallop Mark A.
Susikumar Vivek
Woiwode Thomas W.
Xu Feng
Dorsey & Whitney LLP
Lambkin Deborah C.
Worrall Timothy A.
LandOfFree
Amino acid derived prodrugs of propofol, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid derived prodrugs of propofol, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid derived prodrugs of propofol, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3811949